Enanta Pharmaceuticals
ENTA
132 hedge funds and large institutions have $338M invested in Enanta Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 49 increasing their positions, 33 reducing their positions, and 21 closing their positions.
131% more call options, than puts
Call options by funds: $496K | Put options by funds: $215K
48% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 33
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
0.82% more ownership
Funds ownership: 91.43% → 92.26% (+0.82%)
1% more funds holding
Funds holding: 131 → 132 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less capital invested
Capital invested by funds: $416M → $338M (-$78M)
Top Buyers
| 1 |
SSC
Spruce Street Capital
New York
|
+$7.28M |
| 2 |
Millennium Management
New York
|
+$2.84M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.27M |
| 4 |
KAM
Krensavage Asset Management
New York
|
+$1.34M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$1.34M |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.92M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$2.35M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.58M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.3M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$1.11M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Osaic Holdings
Scottsdale,
Arizona
| – | -$284 | -18 | Closed |
|
|
C
152
Covestor
London,
United Kingdom
| – | -$107 | -8 | -53% |
|
|
SS
153
SBI Securities
Tokyo,
Japan
| – | -$16 | -1 | Closed |
|
ENTA Hedge Fund Activity: Q1 2026 in Review
132 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2026, worth a combined $338M — down 19% from $416M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ENTA positions and 21 closed out — a net gain of 3 holders — while 49 added to existing stakes and 33 trimmed.
The largest buyer was Spruce Street Capital, adding an estimated $7.28M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $6.92M sold.
- 132 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2026, up from 131 in Q4 2025.
- Funds reported $338M of Enanta Pharmaceuticals stock for Q1 2026, down 19% quarter-over-quarter.
- 24 funds opened new Enanta Pharmaceuticals positions in Q1 2026 and 21 closed out, a net change of +3 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2026 was Spruce Street Capital, an estimated $7.28M added.
- The largest Enanta Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $6.92M sold.
Based on aggregated 13F filings for Q1 2026.